- |||||||||| BTX-1188 / BioTheryX
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of BTX-1188 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Sep 18, 2023
P1, N=8, Terminated,
N=168 --> 8 | Trial completion date: May 2026 --> Sep 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Sep 2023; Business decision
- |||||||||| Review, Journal: Targeting cereblon in hematologic malignancies. (Pubmed Central) - Aug 7, 2022
This review describes novel thalidomide analogs, immunomodulatory drugs, also known as CRBN E3 ubiquitin ligase modulators or molecular glues (avadomide, iberdomide, CC-885, CC-90009, BTX-1188, CC-92480, CC-99282, CFT7455, and CC-91633), and CRBN-based proteolysis targeting chimeras (PROTACs) with increased efficacy and potent activity for application in hematologic malignancies...Proteins that are traditionally difficult to target (transcription factors and oncoproteins) can be polyubiquitinated and degraded in this way. The competition of CRBN neosubstrates with endogenous CRBN-interacting proteins and the pharmacology and rational combination therapies of and mechanisms of resistance to CRL4 modulators or CRBN-based PROTACs are described.
- |||||||||| BTX-1188 / BioTheryX
Enrollment open, Metastases: A Study of BTX-1188 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Jan 25, 2022
P1, N=168, Recruiting,
BTX-1188 has entered phase 1 clinical studies for advanced solid tumors and AML. Not yet recruiting --> Recruiting
|
